anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
Participants found to be eligible to take part in this study, participant will have a 18F-FAraG PET scan as described below. Before you start treatment, you will have standard-of-care imaging and then undergo the research 18F-FAraG PET scan. About 20 minutes before the injection of the 18F-FAraG imaging tracer, you will drink two 8-ounce bottles of water to help clear the imaging tracer from your kidneys.
Skeletal muscle mitochondrial defects are a sine qua non of insulin resistance in patients with T2DM. Pioglitazone decreases free fatty acid levels and restores mitochondria number in adipose tissue whereas high fat diet and lipid infusion decreases genes involved in mitochondrial biogenesis. Increased lipid flux from diet or adipose tissue into skeletal muscle might be the cause of decreased mitochondrial biogenesis. The purpose of this study is to determine if 22 weeks treatment with Pioglitazone can increase mitochondrial biogenesis in muscle in 30 uncomplicated T2DM patients that were previously not taking TZD's. This Phase IV, randomized, double-blind, placebo controlled, clinical trial will consist of 3 phases: a screening, a placebo / Pioglitazone phase (12 weeks) and a weight loss period (6-10 weeks). The primary endpoint is to identify the changes in skeletal muscle mitochondria number and gene expression. Secondary endpoints include MRS measured mitochondrial capacity, insulin sensitivity for glucose disposal and insulin suppression of free fatty acids, electron transport chain activity, mitochondrial content and intra hepatic and intra myocellular lipid. Metformin and Sulfonylurea will be used as standardized oral therapy to maintain HbA1C \< 7.0. After completing the protocol, patients will be offered a very low calorie liquid diet (800kcal/d) to assist them in losing weight. During this period they will continue on their previously randomized treatment. When patients lose 10% of their body weight, patients will be switched to a weight maintenance diet (meal replacement with 1 can of glucerna at breakfast and lunch with a "healthy" dinner) for 10 days. MRS measured mitochondrial capacity will again be determined to see if weight loss + pioglitazone has more effect on mitochondrial function than pioglitazone alone.
The invention discloses an application of RARES 2 gene in breast cancer brain transfer diagnosis and treatment. The gene expression difference between a primary tumor of human breast cancer and a brain metastasis tumor is compared by mining public databases such as GEO, MET500 and the like, an RARES 2 gene is obtained by screening and comparing, and the expression of the RARES 2 gene in breast cancer bone metastasis, lung metastasis and liver metastasis is compared. Next, single cell transcriptome sequencing was performed on brain metastases from breast cancer patients. The results show that the expression level of RARRES2 in breast cancer brain metastasis is significantly lower than that of primary tumor, but the expression of RARRES2 in breast cancer bone, lung and liver metastasis is not significantly different from that of primary tumor, suggesting that it is specifically associated with breast cancer brain metastasis. Through constructing an RARES 2 overexpression and knocking down human breast cancer brain metastasis cell (MDA-MB-231) line, the RARES 2 overexpression is found to obviously inhibit the proliferation and invasion of the cell. Through constructing a luciferase-labeled RARES 2 overexpression breast cancer brain transfer mouse model, the RARES 2 overexpression is found to obviously inhibit the proliferation of breast cancer cells in the brain.
Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of chronic liver disease globally. It initiates with simple steatosis (NAFL) and can progress to the more severe condition of non-alcoholic steatohepatitis (NASH). NASH often advances to end-stage liver diseases such as liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Notably, the transition from NASH to end-stage liver diseases is irreversible, and the precise mechanisms driving this progression are not yet fully understood. Consequently, there is a critical need for the development of effective therapies to arrest or reverse this progression. This review provides a comprehensive overview of the pathogenesis of NASH, examines the current therapeutic targets and pharmacological treatments, and offers insights for future drug discovery and development strategies for NASH therapy.
Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
The present invention involves a composition of matter comprising amphotericin B and hydroxyalkyl-gamma-cyclodextrin. The hydroxyalkyl-gamma-cyclodextrin is preferably hydroxypropyl-gamma-cyclodextrin, most preferably 2-hydroxypropyl-gamma-cyclodextrin. The cyclodextrin utilized in the practice of the present invention comprises rings of eight glucose units bound in 1-4 glucosidic linkages, each glucose unit having a hydroxyalkyl radical in ether linkage. The hydroxyalkyl radical is bound in ether linkage to carbon-5 of the glucose unit. The composition of matter of the present invention preferably comprises a cyclodextrin ring of eight glucose units bound in 1-4 glucosidic linkages, substantially each glucose unit having a 2-hydroxypropyl radical in ether linkage. The present invention also involves a method for the treatment of an animal with fungal infection. This method comprises administering to the animal a fungicidally effective amount of a composition of matter as described above comprising amphotericin B and hydroxyalkyl-gamma-cyclodextrin. The administration is preferably parenteral, particularly for disseminated fungal infection, but could be internal or topical, depending upon the particular site of fungal infection and desires of the treating physician. The disseminated fungal infection most preferably treated is a yeast infection such as a Candida albicans, Candida tropicalis, Candida parapsiloses or Torulopsis glabrata infection. The fungicidally effective amount useful for treatment of disseminated fungal infection contains between about 0.4 mg amphotericin B per kg body weight and about 4.0 mg amphotericin B per kg body weight.
A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
A 70-year-old man with complex multimorbidity and intellectual disability was my patient for the last 5 years of his life. He taught me important lessons about the challenges of practicing medicine as a primary care physician. He embodied all the complexities of multimorbidity, the ways in which clinical decision making can be fraught with uncertainties and tradeoffs. He raised difficult ethical questions for his care team, questions about how to respect the dignity of patients who lack decisional capacity and who do not have surrogate decision makers. The gaps in his care revealed shortcomings of the US health care system, but his care in his final years also showed some of the bright spots in coordinated, team-based care. Most importantly, caring for this patient taught me about the rewards of the human connections that primary care physicians establish with their patients.
PROBLEM TO BE SOLVED: To obtain an antimicrobial agent containing a specific compound as an active ingredient, having anti-Helicobacter pylori action, effective in preventing relapse of duodenal ulcer and gastric ulcer and useful for preventing gastric cancer. SOLUTION: This antimicrobial agent contains 1-amino-2-[4-<4-(1- piperidinomethyl)pyridyl-2-oxy>-cis-2-butenylamino]-1-cyclobutene-3,4- dione compound or its salt as an active ingredient. Hydrochloride of the compound is preferably used as the active ingredient. The dose of the ingredient is preferably 5-80mg. Administration form may be any of oral agent, injection and rectal suppository. When an injection is prepared, a pH adjuster, a buffer, a stabilizer, etc., may be added thereto. When oral solid agent is prepared, a vehicle, a binder, a disintegrator, a lubricant, etc., thereto and the mixture is formed into a formulation of tablet, granule, capsule, etc.
PURPOSE: To obtain the subject protein useful for the development of medicines by the screening of agonist/antagonist against a receptor protein for controlling the functions of stomach and small intestine, and to obtain a DNA coding the protein. CONSTITUTION: This G protein conjugated type receptor protein containing the substantially same amino acid sequence as an amino acid sequence of the formula, and a DNA containing a base sequence coding the protein. All RNAs are prepared from the gastrophyloric smooth muscle of a rabbit by a guanidine isothiocyanate method, and poly (A)<+> RNA fraction is prepared from the all RNAs with a mRNA purification kid (Pharmacia Co.). The poly (A)<+> RNA fraction is mixed with random DNA hexamer (BRL Co.) as a primer. A cDNA is synthesized with the reverse transcriptase (BRL Co.) of Moloney mouse leukemia virus in a buffer, and subsequently multiplied by a PCR method to form a transformant. A transformant having a cDNA insertion fragment, E. coli JM109/pMH 28 (FERM BP-4970), is obtained, and the base sequence is determined.
Markers that can be identified in the EBC of patients with asthma include pH, hydrogen peroxide, nitrogen oxides, eicosanoids, isoprostanes, adenosine, certain cytokines, chemokines, and growth factors. Concentrations of these biomarkers are influenced by inflammation, oxidative stress, and can be modulated by therapeutic interventions. There is evidence that some markers in EBC differ between patients with asthma and controls, and some of them can correlate with asthma severity score, lung function. The aim of this study is to evaluate the effect of allergic disease, disease monitoring and exposure to tobacco smoke on airway inflammation measured by markers in exhaled breath condensate (EBC) in children with asthma allergic to house dust mite. We will also evaluate the effect of antiasthmatic treatment applied out of dust season on the number of exacerbations in "asthma epidemic" in September. We will evaluate the effect of exposure to tobacco smoke on antiasthmatic treatment.

Also, we aim to assess correlations between cytokine concentrations in EBC and clinical characteristic of the patients with exercise-induced bronchoconstriction (EIB) as another phenotype of asthma. At the first study vist patients with EIB underwent fractional exhaled nitric oxide measurement (FeNO) and baseline spirometry, performed exercise treadmill challenge (ETC) and EBC samples were obtained at the end of ETC.
The ABIRISK (Anti-biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk) consortium, within the IMI (Innovative Medicines Initiative), is a Public Private Partnership between pharmaceutical companies, academic institutions and clinical centers. The ABIRISK aims are to better analyze and predict the phenomenon of immunogenicity in order to reduce its occurrence. One of the main objectives of ABIRISK is to set up prospective cohort (ABI-RA) of patients with rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA) to provide, using an integrated approach, new tools for being able to detect earlier and even before the beginning of the therapy, immunization to biopharmaceutical (BP). The introduction of BP has been a critical step forward in care for RA/JIA and 9 BP are now licensed for the treatment of RA/JIA. In spite of this progress, failure of response to BP is frequent and in most of the registries, less than 50 % of patients are still on drug at 5 years. These failures may be primary failures or secondary failures. The fact is that the low level of responses becomes insufficient compared to the expectations. One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients. ADAb may decrease the efficacy of BPs by neutralizing them or modifying their clearance and they may be associated with BP-specific hypersensitivity reactions. The prediction, prevention and cure of anti-drug (AD) immunization are thus major goals in BP development. This prospective study (ABI-RA) will assess the occurrence of ADAb using standardized and validated assay(s) and also cellular, genetic and molecular parameters in RA/JIA patients treated with adalimumab, etanercept, infliximab and rituximab or tocilizumab, to address the mechanism of immunogenicity. Patient-related factors that might predispose an individual to an immune response will be taken into account: underlying disease, genetic background, immune status, including immunomodulating therapy and dosing schedule.
The invention provides a traditional Chinese medicine composition for promoting sputum excretion. The composition is formed by utilizing ginkgo leaf tablets as the main component and matching fig, Chinese yam, eleusine indica, moleplant seed, mulberry, camellia, phoenix-tail fern, honeysuckle and cucumber. Despite the above components do not have direct promotion effects on sputum excretion based on the existing medical cognitive level, the fact that the traditional Chinese medicine composition obtained by conducting integration and optimized design on the components according to usage can effectively prompt sputum excretion of a patient is found accidentally by experiments. The composition is high in effect and free of side effects. Based on the found fact, an applicant acquires the traditional Chinese medicine composition. The composition achieves prominent technical effects by means of ingenious material selection and reasonable dosage, meanwhile is low in cost and easy to achieve, and has prominent popularization prospects.
Currently, the gold standard for assessment of lung function in chronic respiratory disease is spirometry. This is combined with anatomical imaging (chest x-ray and computed tomography) for structural assessment. Spirometry only measures global lung function. It provides no information regarding the different regions of the lung or about the supporting "framework" of the lung itself, the parenchyma. In addition, changes in lung function as measured with spirometric indices do not correlate coherently with the symptoms experienced by patients, nor reflect their decline in health. This weak relationship is probably because the lung is a complex regional organ where localized disturbances of a variety of factors including gas flow (ventilation), blood flow (perfusion) and gas transfer all combine to impair respiratory function.

MRI has the advantage of being an imaging technique free from ionizing radiation making it safe and practical for diseases such as asthma and obstructive lung disease where repeated follow-up scans are necessary. Hyperpolarized xenon, in the doses given for imaging has been shown to be safe. Conventional MRI has limited use in respiratory disease, because the lung is largely composed of air spaces that do not generate an MR signal. Hyperpolarized noble gases can resolve this problem.
At present, there is no proven drug or modality to stabilize the vulnerable plaques. A number of drugs that are beneficial for patients with coronary disease may act in part by improving the stability of plaques that are vulnerable for future rupture. Especially, Lipid-lowering therapy, particularly with statins, can stabilize vulnerable plaques or those that have already ruptured by improving endothelial function and reducing thrombogenicity, platelet aggregation, and possibly inflammation. As the atherosclerotic disease has progressed, there is an increase of the atherosclerotic plaque amounts. However, the changes of specific plaque compositions within the atherosclerotic lesions have not been sufficiently evaluated. Previous pathologic findings reported that there was a significant relation between the plaque size and necrotic core size.Conventional grey-scale intravascular ultrasound (IVUS) has significant limitations in accurately assessing atheromatous plaque composition. These limitations have been partially addressed by radiofrequency signal processing with spectral analysis of the back-scattered ultrasound signals. Using this technology, Virtual Histology (VH) IVUS is capable of characterizing plaque as calcified (white), fibrotic (dark-green), fibrofatty (yellow-green), and necrotic core (red). In addition, optical coherence tomography (OCT) is a light-based imaging modality that can be used in biological systems to study tissues in vivo with near-histologic, ultrahigh resolution. The rationale for intravascular application of OCT is its potential for in vivo visualizations of the coronary artery microstructure. This unique image resolution of OCT offers the potential to detect key features of vulnerable plaque in vivo. Beyond the inherent limitations of angioscopy and intravascular ultrasound, OCT might offer a much higher sensitivity in the detection of necrotic/lipid cores within coronary atheromas. Therefore, plaque characterization using VH-IVUS and OCT may provide detailed morphologic insights of plaque vulnerability.

We hypothesized that statin would provide benefits to stabilize coronary plaque composition by LDL-reduction and/or a pleiotropic effect. We also hypothesized that high-dose statin would be more beneficial in reducing the vulnerable plaque and stabilizing the vulnerable plaque composition than low-dose statin.
A topical sanitizing composition for restoring skin's natural balance of bacteria is provided. The topical sanitizing composition includes about 0.02 wt. % to 10.0 wt. % of an active ingredient, at least about 40 wt. % of one or more C1-6 alcohols; and water. The active ingredient comprises one or more of a probiotic, probiotic derivative, and a prebiotic.
<P>PROBLEM TO BE SOLVED: To provide a function allowing a consumer to create or correct a self image according to its recognition of reality.  <P>SOLUTION: A method and an apparatus for correction of the body image can be used for a target person to correct the body image of the target person based on the self evaluation of an actual state of a body of the target person itself. It is possible for the target person to be encouraged to capture a primitive body image by using an image capturing apparatus. It is also possible for the target person to be encouraged to execute the self evaluation of the actual state of the body of the target person itself. It is possible for the primitive body image to be corrected so as to reflect the self evaluation of the target person based on his reaction to the encouragement for the self evaluation.  <P>COPYRIGHT: (C)2004,JPO
The natural next step in this program of research is to investigate interventions for reversing pharyngeal sarcopenia with the ultimate goal of developing novel therapeutic strategies to address this pervasive clinical issue. The exercise science literature suggests that sarcopenia in the limb muscles can be reversed through a combination of rigorous exercise and adequate levels of dietary protein. The innovative multi-disciplinary protocol, PEPP (Pharyngeal Exercises Plus Protein), combines pharyngeal swallowing exercises selected for their known activation of the pharyngeal muscles with daily supplemental protein drinks. The research lab had documented successful improvements to swallowing physiology and pharyngeal sarcopenia in a pilot series of 5 older women using PEPP. However the research was abruptly halted due to both ethical and feasibility challenges posed by the COVID-19 pandemic. In response to these challenges, this study is seeking to establish the feasibility and effectiveness when the PEPP intervention is delivered using telehealth (telePEPP).
PROBLEM TO BE SOLVED: To obtain a tyrosinase inhibitor having higher inhibitory activity than that of the conventional tyrosinase inhibitor and higher stability by using a specific extract from the grains of Tatary buckwheat (Fagopyrum tataricum). SOLUTION: The grains of Tatary buckwheat cultured at Yunnan in China or in Nepal are used as a raw material to effect extraction with aqueous acetone and the extract is used as an active ingredient. The extract may be directly used as it is, but cis-umbellic acid (1,4-dihydroxy cis-cinnamic acid) of the formula isolated from the extract may be used. As the raw material, the outer skins after using the core of the grains (the first flour) can be preferably used. The extract obtained from the outer skins has particularly high ability to inhibit tyrosinase. This tyrosinase inhibitor is safe to human body and can be used as a browning preventive for fruits and vegetables and also as a food additive for cut fruits and cut vegetable.